EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines

European Urology

Volumn 65, Issue 4, 2014, Pages 778-792

  Witjes, J Alfred ^a   Compérat, Eva ^b   Cowan, Nigel C ^c   De Santis, Maria ^d   Gakis, Georgios ^e   Lebret, Thierry ^f   Ribal, Maria J ^g   Van Der Heijden, Antoine G ^a   Sherif, Amir ^h  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UK yvonne digestiblenutritioncouk   (United Kingdom)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^g UNIVERSITY OF BARCELONA   (Spain)

^h UMEÅ UNIVERSITY   (Sweden)

Author keywords

Bladder cancer; Bladder sparing treatments; Chemotherapy; Cisplatin based; Comorbidities; Cystectomy; EAU guidelines; Infiltrative; Invasive; Quality of life

Indexed keywords

BCG VACCINE; CALCIUM; CARBOPLATIN; CARCINOGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DENOSUMAB; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINFLUNINE; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT CHEMOTHERAPY; BLADDER METASTASIS; BLADDER SURGERY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL EVALUATION; CLINICAL PROTOCOL; COMORBIDITY; COMPUTED TOMOGRAPHIC UROGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYSTECTOMY; CYSTOSCOPY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HAZARD RATIO; HUMAN; LUNG; LYMPH NODE DISSECTION; MEDICAL EXPERT; METASTATIC BLADDER CANCER; MONOTHERAPY; MUSCLE INVASIVE BLADDER CANCER; NEPHROURETERECTOMY; NON MUSCLE INVASIVE BLADDER CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; PHYSICAL EXAMINATION; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING; TRANSURETHRAL RESECTION; TRANSURETHRAL RESECTION OF THE BLADDER; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME; URINARY DIVERSION; UROGRAPHY; VITAMIN SUPPLEMENTATION; WORK;

BLADDER CANCER; BLADDER SPARING TREATMENTS; CHEMOTHERAPY; CISPLATIN-BASED; COMORBIDITIES; CYSTECTOMY; EAU GUIDELINES; INFILTRATIVE; INVASIVE; QUALITY OF LIFE;

COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 84894420746     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.11.046     Document Type: Article

References (105)

1. A. Stenzl, N.C. Cowan, and M. De Santis et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2011 1009 1018
2. Witjes JA, Compérat E, Cowan C, et al. members of the EAU Guidelines Panel on Muscle-invasive and Metastatic Bladder Cancer. Guidelines on muscle-invasive and metastatic bladder cancer. Presented at: EAU Annual Congress 2013; March 15-19, 2013; Milan, Italy.
3. M. Ploeg, K.K. Aben, and L.A. Kiemeney The present and future burden of urinary bladder cancer in the world World J Urol 27 2009 289 293
4. N.D. Freedman, D.T. Silverman, and A.R. Hollenbeck et al. Association between smoking and risk of bladder cancer among men and women JAMA 306 2011 737 745
5. S. Gandini, E. Botteri, and S. Iodice et al. Tobacco smoking and cancer: a meta-analysis Int J Cancer 122 2008 155 164
6. P. Brennan, O. Bogillot, and S. Cordier et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies Int J Cancer 86 2000 289 294
7. C.L. Pashos, M.F. Botteman, and B.L. Laskin et al. Bladder cancer: epidemiology, diagnosis, and management Cancer Pract 10 2002 311 322
8. M. Harling, A. Schablon, and G. Schedlbauer et al. Bladder cancer among hairdressers: a meta-analysis Occup Environ Med 67 2010 351 358
9. M. Kogevinas, A. t'Mannetje, and S. Cordier et al. Occupation and bladder cancer among men in Western Europe Cancer Causes Control 14 2003 907 914
10. A.M. Nieder, M.P. Porter, and M.S. Soloway Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study J Urol 180 2008 2005 2009 discussion 2009-10
11. M.J. Zelefsky, D.M. Housman, and X. Pei et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer Int J Radiat Oncol Biol Phys 83 2012 953 959
12. A. Vaidya, M.S. Soloway, and C. Hawke et al. De novo muscle invasive bladder cancer: is there a change in trend? J Urol 165 2001 47 50
13. M. May, C. Stief, and S. Brookman-May et al. Gender-dependent cancer-specific survival following radical cystectomy World J Urol 30 2012 707 713
14. L.H. Sobin, M. Gospodariwicz, and C. Wittekind TNM classification of malignant tumors ed. 7. 2009 Wiley-Blackwell Hoboken, NJ 262 265
15. G. Sauter, F. Algaba, and M. Amin et al. Tumours of the urinary system: non-invasive urothelial neoplasias J.N. Eble, G. Sauter, Epstein Jl I. Sesterhenn, WHO classification of tumors of the urinary system and male genital organs 2004 IARC Press Lyon, France 29 34
16. D.E. Hansel, M.B. Amin, and E. Comperat et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens Eur Urol 63 2013 321 332
17. S. Baltaci, O. Adsan, and O. Ugurlu et al. Reliability of frozen section examination of obturator lymph nodes and impact on lymph node dissection borders during radical cystectomy: results of a prospective multicentre study by the Turkish Society of Urooncology BJU Int 107 2011 547 553
18. R.J. Yu, J.P. Stein, and J. Cai et al. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy J Urol 176 2006 493 498 discussion 498-9
19. D. Tilki, O. Reich, and P.I. Karakiewicz et al. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome Eur Urol 58 2010 112 117
20. G. Gakis, D. Schilling, and M. Renninger et al. Comparison of the new American Joint Committee on Cancer substratification in node-negative pT2 urothelial carcinoma of the bladder: analysis of patient outcomes in a contemporary series BJU Int 107 2011 919 923
21. A.P. Mitra, E.C. Skinner, and G. Miranda et al. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer BJU Int 111 2013 240 248
22. M. Ploeg, L.A. Kiemeney, and G.A. Smits et al. Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy Urol Oncol 30 2012 247 251
23. M.U. Mungan, A.E. Canda, and E. Tuzel et al. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder Eur Urol 48 2005 760 763
24. W. Kassouf, P.E. Spiess, and G.A. Brown et al. Prostatic urethral biopsy has limited usefulness in counselling patients regarding final urethral margin status during orthotopic neobladder reconstruction J Urol 180 2008 164 167 discussion 167
25. G. Gakis, D. Schilling, and J. Bedke et al. Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery BJU Int 105 2010 468 471
26. A. Rajesh, H.K. Sokhi, and R. Fung et al. Bladder cancer: evaluation of staging accuracy using dynamic MRI Clin Radiol 66 2011 1140 1145
27. S. Yoshida, F. Koga, and S. Kobayashi et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer Int J Radiat Oncol Biol Phys 83 2012 e21 e27
28. N.C. Cowan CT urography for hematuria Nat Rev Urol 9 2012 218 226
29. L.S. Mertens, A. Fioole-Bruining, and E. Vegt et al. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle BJU Int 112 2013 729 734
30. Babjuk M, Oosterlinck W, Sylvester R, et al., members of the EAU Guidelines Panel on Non-muscle Invasive Bladder Cancer. Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Presented at: EAU Annual Congress 2013; March 15-19, 2013; Milan, Italy.
31. P.U. Malmström, R.J. Sylvester, and D.E. Crawford et al. An individual patient data meta-analysis of the longterm outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette- Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
32. M. Duchek, R. Johansson, S. Jahnson members of the Urothelial Cancer Group of the Nordic Association of Urology Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer: a prospective, randomized, Nordic study Eur Urol 57 2010 25 31
33. S. van den Bosch, and A.J. Witjes Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review Eur Urol 60 2011 493 500
34. M. Brake, H. Loertzer, and R. Horsch et al. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin J Urol 163 2000 1697 1701
35. V. Pansadoro, P. Emiliozzi, and L. Defidio et al. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results J Urol 154 1995 2054 2058
36. J.P. Stein, and D.G. Skinner Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure World J Urol 24 2006 296 304
37. R. Rosenblatt, A. Sherif, and E. Rintala et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer Eur Urol 61 2012 1229 1238
38. K. Nishimura, C. Fujiyama, and K. Nakashima et al. The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall Int Urol Nephrol 41 2009 869 875
39. C.N. Sternberg, V. Pansadoro, and F. Calabrò et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 97 2003 1644 1652
40. A. Sherif, L. Holmberg, E. Rintala Nordic Urothelial Cancer Group Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies Eur Urol 45 2004 297 303
41. Advanced Bladder Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 2003 1927 1934
42. E. Winquist, T.S. Kirchner, R. Segal Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis J Urol 171 2004 561 569
43. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 202 206 discussion 205-6
44. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group; Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
45. C. Bolenz, R. Ho, and G.R. Nuss et al. Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival BJU Int 106 2010 1324 1329
46. G. Lughezzani, M. Sun, and S.F. Shariat et al. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer Cancer 117 2011 103 109
47. R. Mayr, M. May, and T. Martini et al. Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder BJU Int 110 2012 E222 E227
48. T.M. Morgan, K.A. Keegan, and D.A. Barocas et al. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy J Urol 186 2011 829 834
49. F. Abdollah, M. Sun, and J. Schmitges et al. Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study Ann Surg Oncol 19 2012 309 317
50. R. Mayr, M. May, and T. Martini et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder Eur Urol 62 2012 662 670
51. B. Malavaud, C. Vaessen, and M. Mouzin et al. Complications for radical cystectomy impact of the American Society of Anesthesiologists score Eur Urol 39 2001 79 84
52. S.S. Chang, J.M. Hassan, and M.S. Cookson et al. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage J Urol 170 2003 1085 1087
53. R.F. Sánchez-Ortiz, W.C. Huang, and R. Mick et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma J Urol 169 2003 110 115 discussion 115
54. J.B. Jensen, B.P. Ulhøi, and K.M. Jensen Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery BJU Int 106 2010 199 205
55. A.R. Zlotta Limited, extended, superextended, megaextended pelvic lymph node dissection at the time of radical cystectomy: what should we perform? Eur Urol 61 2012 243 244
56. Bruins M, Veskimae E, Hernandez V, et al. Systematic review of role and extent of lymphadenectomy during radical cystectomy for cN0M0 muscle invasive bladder cancer: methods protocol. EAU MIBC Guideline 2013 update. http://www.uroweb.org/gls/refs/Systematic-methodology-Bladder-Cancer-2013- update.pdf.
57. A. Karl, P.R. Carroll, and J.E. Gschwend et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer Eur Urol 55 2009 826 835
58. R. Svatek, and P. Zehnder Role and extent of lymphadenectomy during radical cystectomy for invasive bladder cancer Curr Urol Rep 13 2012 115 121
59. A.J. Figueroa, J.P. Stein, and M. Dickinson et al. Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients Cancer 83 1998 141 147
60. R.E. Hautmann, R.C. de Petriconi, and B.G. Volkmer Lessons learned from 1,000 neobladders: the 90-day complication rate J Urol 184 2010 990 994 quiz 1235
61. M. Kilciler, S. Bedir, and F. Erdemir et al. Comparison of ileal conduit and transureteroureterostomy with ureterocutaneostomy urinary diversion Urol Int 77 2006 245 250
62. A. Pycha, E. Comploj, and T. Martini et al. Comparison of complications in three incontinent urinary diversions Eur Urol 54 2008 825 834
63. C. Wiesner, R. Bonfig, and R. Stein et al. Continent cutaneous urinary diversion: long-term follow-up of more than 800 patients with ileocecal reservoirs World J Urol 24 2006 315 318
64. R.E. Hautmann, R.C. de Petriconi, and B.G. Volkmer 25 years of experience with 1,000 neobladders: long-term complications J Urol 185 2011 2207 2212
65. R.E. Hautmann, B.G. Volkmer, and M.C. Schumacher et al. Long-term results of standard procedures in urology: the ileal neobladder World J Urol 24 2006 305 314
66. M.P. Porter, and D.F. Penson Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature J Urol 173 2005 1318 1322
67. J.A. Eastham Do high-volume hospitals and surgeons provide better care in urologic oncology? Urol Oncol 27 2009 417 421
68. J.H. Ok, F.J. Meyers, and C.P. Evans Medical and surgical palliative care of patients with urological malignancies J Urol 174 2005 1177 1182
69. A.K. Goel, M.S. Rao, and A.G. Bhagwat et al. Intravesical irrigation with alum for the control of massive bladder hemorrhage J Urol 133 1985 956 957
70. M. Huncharek, J. Muscat, and J.F. Geschwind Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis Anticancer Res 18 1998 1931 1934
71. N.H. Slack, I.D. Bross, and G.R. Prout Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder J Surg Oncol 9 1977 393 405
72. A. Widmark, P. Flodgren, and J.E. Damber et al. A systematic overview of radiation therapy effects in urinary bladder cancer Acta Oncol 42 2003 567 581
73. T. Granfors, R. Tomic, and B. Ljungberg Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma Scand J Urol Nephrol 43 2009 293 299
74. E. Solsona, I. Iborra, and A. Collado et al. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer J Urol 184 2010 475 480
75. M. Milosevic, M. Gospodarowicz, and A. Zietman et al. Radiotherapy for bladder cancer Urology 69 Suppl 2007 80 92
76. M.D. Shelley, J. Barber, and T. Wilt et al. Surgery versus radiotherapy for muscle invasive bladder cancer Cochrane Database Syst Rev 2002 CD002079
77. P.W. Chung, R.G. Bristow, and M.F. Milosevic et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer Urol Oncol 25 2007 303 309
78. C.J. Weight, J.A. Garcia, and D.E. Hansel et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series Cancer 115 2009 792 799
79. F.S. Krause, B. Walter, and O.J. Ott et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment Anticancer Res 31 2011 985 990
80. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 189 201 discussion 199-201
81. D.F. Bajorin, P.M. Dodd, and M. Mazumdar et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy J Clin Oncol 17 1999 3173 3181
82. H. von der Maase, L. Sengelov, and J.T. Roberts et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608
83. S.K. Pal, and A. Hurria Impact of age, sex, and comorbidity on cancer therapy and disease progression J Clin Oncol 28 2010 4086 4093
84. A. Bamias, E. Efstathiou, and L.A. Moulopoulos et al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy Ann Oncol 16 2005 307 313
85. C.N. Sternberg, A. Yagoda, and H.I. Scher et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse Cancer 64 1989 2448 2458
86. H. von der Maase, S.W. Hansen, and J.T. Roberts et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
87. C.N. Sternberg, P. de Mulder, J.H. Schornagel EORTC Genito-Urinary Cancer Group Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Eur J Cancer 42 2006 50 54
88. J. Bellmunt, H. von der Maase, and G.M. Mead et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987 J Clin Oncol 30 2012 1107 1113
89. A. Dash, M.D. Galsky, and A.J. Vickers et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder Cancer 107 2006 506 513
90. M. De Santis, J. Bellmunt, and G. Mead et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC Study 30986 J Clin Oncol 30 2012 191 199
91. P. Albers, R. Siener, M. Härtlein German TCC Study Group of the German Association of Urologic Oncology Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life Onkologie 25 2002 47 52
92. J. Bellmunt, C. Théodore, and T. Demkov et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract J Clin Oncol 27 2009 4454 4461
93. A.O. Siefker-Radtke, G.L. Walsh, and L.L. Pisters et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience J Urol 171 2004 145 148
94. R.E. Coleman Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 2001 165 176
95. D.H. Henry, L. Costa, and F. Goldwasser et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 2011 1125 1132
96. World Health Organization (WHO) Consensus Conference on Bladder Cancer R.E. Hautmann, H. Abol-Enein, and K. Hafez et al. Urinary diversion Urology 69 Suppl 2007 17 49
97. R. Autorino, G. Quarto, and G. Di Lorenzo et al. Health related quality of life after radical cystectomy: comparison of ileal conduit to continent orthotopic neobladder Eur J Surg Oncol 35 2009 858 864
98. A. Stenzl, H. Sherif, and M. Kuczyk Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results Int Braz J Urol 36 2010 537 547
99. J. Philip, R. Manikandan, and S. Venugopal et al. Orthotopic neobladder versus ileal conduit urinary diversion after cystectomy - a quality-of-life based comparison Ann R Coll Surg Engl 91 2009 565 569
100. R.C. Hedgepeth, S.M. Gilbert, and C. He et al. Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions Urology 76 2010 671 675
101. D.F. Roychowdhury, A. Hayden, and A.M. Liepa Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer J Clin Oncol 21 2003 673 678
102. S.B. Malkowicz, H. van Poppel, and G. Mickisch et al. Muscle-invasive urothelial carcinoma of the bladder Urology 69 Suppl 2007 3 16
103. M.J. Mathers, J. Zumbe, and S. Wyler et al. Is there evidence for a multidisciplinary follow-up after urological cancer? an evaluation of subsequent cancers World J Urol 26 2008 251 256
104. M.A. Ghoneim, M. Abdel-Latif, and M. el-Mekresh et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later J Urol 180 2008 121 127
105. V. Soukup, M. Babjuk, and J. Bellmunt et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature Eur Urol 62 2012 290 302